CMND -
Clearmind Medicine Inc. Common Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 0.21 -0.03 (-13.17%) |
0.0 (-0.33%) |
0.0 (-0.6%) |
-0.01 (-2.73%) |
0.0 (0.72%) |
-0.03 (-13.69%) |
0.0 (-2.2%) |
0.01 (5.5%) |
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 58.97
- VWAP:
- 0.18
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight
Apr 28, 2025 17:00
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Apr 25, 2025 11:59
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Apr 25, 2025 11:55
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
Jan 02, 2025 12:45
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Dec 26, 2024 11:59
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Dec 24, 2024 11:55
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight
Dec 11, 2024 18:00
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
Aug 06, 2024 12:57
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - GlobeNewswire
Jul 16, 2024 10:05
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
Jun 28, 2024 11:55